Global Markets

Q3: Sartorius says lean manufacturing drives margins

Sartorius says its focus on lean manufacturing and creating additional capacity has pushed its margins up, but increased headcount will have an impact going forward. For the first nine months of 2021, German life sciences firm Sartorius reported group sales revenue of €2.6 billion ($3 billion), an increase of 50.4% year-on-year. The firm highlighted strong demand for its bioprocessing services and consumables as a major factor in this growth, with the division contributing almost €2 billon to the top line.…

CureVac manufacturing switch-up as it shelves COVID-19 vax

CureVac will shift its manufacturing setup to produce clinical material for second-generation mRNA vaccine candidates as it abandons CVnCoV.   Just one month ago, CureVac dropped two contract development manufacturing organization’s (CDMOs) after demand for mRNA COVID-19 candidate CVnCoV diminished but the firm remained confident future clinical trials would still go ahead.   Now, CureVac has decided to withdraw the first-generation vaccine candidate from the approval process with the European Medicines Agency (EMA) in a bid to “refocus efforts on improved second-generation vaccine candidates we are developing in collaboration with GSK.” According to the firm, its second-generation candidates are based on an improved mRNA setup and includes flu…

Lonza ups mammalian cell services in Singapore

The increased capabilities in Singapore will support both upstream and downstream processing and analytical development, the CDMO says. The size of the investment has not been disclosed, but Jeetendra Vaghjiani, senior director of Clinical Development for Mammalian Biologics, Lonza told this publication the expansion consists of a 1800 m2 lab built at the Singapore Science Park in Tuas along with the renovation of an existing 1500 m2 lab. “We are adding more capacity across all our technologies, supporting upstream and…

How biopharma dealt with COVID: ‘We science-ed the crap out of it!’

COVID-19 showed biopharma at its best and worst says a former regulator, who argues that the scrutiny which came with the pandemic highlighted some key industry challenges. The pandemic put biopharma in the spotlight according to Jeff Baker, former deputy director of the Office of Biotechnology Products in CDER, who told delegates at the BPI East hybrid conference last month the crisis highlighted industry’s strengths and weaknesses. “There will be a lot of books written about the COVID-19 crisis and…

Boosters and beyond: CDMOs likely to continue to ride COVID-19 wave

Inoculating children and booster jabs will further fuel CDMO demand argues GlobalData’s Fiona Barry, who adds industry’s reliance on third-party manufacturers will not abate post-pandemic. Since the start of the pandemic, biopharma’s efforts and determination in developing and producing billions of vaccines and therapeutics have led to some companies and sectors benefitting from a COVID-19 windfall. The contract development and manufacturing organization (CDMO) sector is one such group, with both drug substance and drug product capacity proving crucial in the…

Moderna lays plans for $500m African mRNA plant

Details remain under wraps, but the $500 million investment will lead to Moderna’s first biomanufacturing facility outside of North America. Moderna, which sprang to the forefront of biopharma on the back of the success of its COVID-19 vaccine, announced yesterday it will invest up to $500 million into a facility on the African continent to support production of its messenger RNA portfolio. While the exact location (Africa is a big place!) has not yet been decided, a spokesperson for the…

CDMO BioCina rises out of Pfizer’s Australian ashes

Bridgewest Group has launched BioCina, a microbial therapy and mRNA-based manufacturer operating from a former Pfizer facility in Adelaide, Australia. Last year, Bridgewest Australia Holdings, a subsidiary of private investment firm Bridgewest Group, entered the biologics production space by inking a deal to acquire a Pfizer plant in Adelaide, Australia. This week, the company has completed an expansion program and relaunched the 60,000 square-foot site under its contract development and manufacturing organization (CDMO) banner BioCina. The Adelaide site now includes…

BioProcess Insider State of the Industry — September 2021 Panel Discussion

Our BioProcess Insider editorial team sits down with Joshua Speidel, PhD Partner, Latham Biopharm Group, Patrick Lucy, President and CEO, Lykan Biosciences, and Amélie Boulais, Head of Market Entry Strategy, Virus Based Therapeutics at Sartorius, to reflect on how the quarterly movements of the wider pharma industry are affecting the biomanufacturing space. Through the analysis of global events, recent deal making, and regulatory and technological advancements, we look to determine the factors driving or squeezing production and pre-empt upcoming trends…

Chinese CDMO market growing rapidly despite talent shortage, says Lonza

Lonza says its presence in China is growing despite a short-term talent shortage in the industry. “The Chinese pharma market is big and growing very quickly [with] a lot of molecules that are in development,” Lonza’s general manager of China, Hong Pan, tells BioProcess Insider. “China was very generically driven but more companies are putting their money into innovative pharma. The added growth is due to a few factors, [such as] the increased wealth of the population. People are getting…

Biocon jumps into vaccines through $4.9bn Serum Institute pact

The strategic alliance will see Biocon access a minimum of 100 million doses of vaccines per year from Serum Insititute’s facility in Pune, India. The two Indian biopharma giants announced Friday a strategic alliance to complement each other’s vaccine and biologics capabilities and manufacturing capacity. “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics,” Biocon’s executive chair Kiran Mazumdar-Shaw said. “Our shared vision of building large scale businesses having global impact makes…